NurExone Biologic Inc. announced financial results for Q3 2025, showcasing $3.2 million in gross proceeds from the exercise of warrants. They also demonstrated dose-dependent vision recovery in a glaucoma model, further supporting the potential of their ExoPTEN therapy. Additionally, they solidified their global scientific presence through various industry presentations and received recognition in prestigious global award competitions.

The company raised $1.4 million through private placements in August and September 2025. They also secured patents in the U.S. and Israel for their exosome production process, strengthening their IP position. Plans for a U.S. manufacturing facility in Indianapolis were announced, with an incentive offer of up to $0.26 million to support the expansion.

NurExone advanced its acute spinal cord injury program in Q3 2025, showing dose-dependent motor recovery in preclinical studies. They also joined the ARMI/BioFabUSA BioFab Startup Lab to enhance their biomanufacturing presence in the U.S. Additionally, they granted restricted share units and stock options to consultants and employees, further incentivizing key personnel.

In Q3 2025, NurExone reported $0.70 million in net R&D expenses, reflecting an increase from the previous year. General and administrative expenses were $0.76 million, slightly lower than Q3 2024. The net financial income was $0.01 million, resulting in a net loss of $1.47 million for the quarter.

CEO Dr. Lior Shaltiel highlighted the company’s progress in strengthening their platform, securing patents, and advancing preclinical programs. CFO Eran Ovadya emphasized disciplined execution of their operating plan and strategic investments. NurExone continues to focus on advancing ExoPTEN towards clinical readiness and expanding their operational capabilities.

Read more at GlobeNewswire: NurExone Biologic Inc. Announces Third Quarter 2025